Company Filing History:
Years Active: 2021-2025
Title: John Rowley Wetterau, II: Innovator in Pharmaceutical Compounds
Introduction
John Rowley Wetterau, II is a notable inventor based in Indianapolis, IN (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific health conditions. With a total of 2 patents to his name, Wetterau's work is recognized for its potential impact on medical treatments.
Latest Patents
Wetterau's latest patents include innovative compounds aimed at addressing critical health issues. One of his patents focuses on sodium-hydrogen exchanger 3 (NHE3) inhibitor compounds. This invention relates to pharmaceutical compositions that utilize these compounds for the treatment of diseases associated with elevated sodium and/or phosphate levels. Another significant patent involves condensed thiophene derivatives that serve as NaPi-IIb inhibitors. This invention provides methods for using these compounds to treat hyperphosphatemia, chronic kidney disease, and cardiovascular diseases linked to chronic kidney disease.
Career Highlights
Wetterau is currently employed at Eli Lilly and Company, a leading pharmaceutical firm known for its commitment to innovation and healthcare solutions. His work at Eli Lilly has allowed him to contribute to the development of groundbreaking treatments that can improve patient outcomes.
Collaborations
Throughout his career, Wetterau has collaborated with esteemed colleagues, including David Andrew Coates and Kevin Robert Fales. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical compounds.
Conclusion
John Rowley Wetterau, II exemplifies the spirit of innovation in the pharmaceutical industry. His contributions through patents and collaborations highlight his commitment to advancing medical science and improving health outcomes.